Evgen Pharma PLC Comment on the COVID-19 vaccine announcement (8922E)
November 11 2020 - 2:00AM
UK Regulatory
TIDMEVG
RNS Number : 8922E
Evgen Pharma PLC
11 November 2020
Evgen Pharma plc
("Evgen" or the "Company")
Comment on COVID-19 vaccine announcement
Evgen Pharma plc (AIM: EVG), a clinical stage drug development
company, notes the recent news that Pfizer have announced the first
interim analysis of a Phase III COVID-19 vaccine. Evgen believe
that multiple approaches will be needed to curtail this virus and
the progress announced earlier this week is a hugely positive
development.
As previously announced, Evgen have entered into a Phase II/III
trial with the University of Dundee to investigate whether the
Company's lead asset, SFX-01, can reduce the severity, or prevent
the onset of, acute respiratory distress syndrome ("ARDS")
including, but not exclusively in patients with suspected COVID-19.
The Company confirms that this study is poised to commence
recruitment, as announced on 23 October 2020 and will be providing
a further update shortly.
The Phase II/III STAR trial (SFX-01 Treatment for Acute
Respiratory Infections) has received all the necessary regulatory
approvals needed to proceed and patient recruitment will begin
shortly. Supplies of SFX-01 have already been delivered to the
centre.
Dr Huw Jones, Evgen CEO, commented: "We are pleased to see such
progress on a potential vaccine against COVID-19. Recently ARDS has
been heavily associated with COVID-19 as it affects the respiratory
tract, but it is and will remain a condition in its own right long
after we have beaten the pandemic and will continue to be a huge
problem for patients. There is a considerable unmet need for
effective treatments for ARDS and the outcome of our study will
hopefully show how we can use SFX-01 in a serious respiratory
condition regardless of the infective agent involved."
Enquiries:
Evgen Pharma plc www.evgen.com via Walbrook
Barry Clare, Chairman
Dr Huw Jones, CEO
Richard Moulson, CFO
finnCap www.finncap.com +44 (0)20 7220 0500
Geoff Nash / Teddy Whiley (Corporate
Finance)
Alice Lane (ECM)
Walbrook PR +44 (0)20 7933 87870 or evgen@walbrookpr.com
+44 (0)7980 541 893 / +44 (0)7876
Paul McManus / Anna Dunphy 741 001
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company
developing sulforaphane based medicines for the treatment of
multiple diseases. The Company's core technology is Sulforadex(R),
a method for synthesising and stabilising the naturally occurring
compound sulforaphane and novel proprietary analogues based on
sulforaphane. The lead product, SFX-01, is a patented composition
of synthetic sulforaphane and alpha-cyclodextrin.
Clinical data from the Company's open-label Phase II STEM trial
has shown that SFX-01 can halt the growth of progressing tumours in
patients with oestrogen-positive (ER+) metastatic breast cancer,
and in some cases significantly shrink the tumour, whilst causing
very few side effects.
The Company commenced operations in January 2008 and has its
headquarters at The Colony, Wilmslow, Cheshire, and its registered
office is at the Liverpool Science Park, Liverpool. It joined the
AIM market of the London Stock Exchange in October 2015 and trades
under the ticker symbol EVG.
For further information, please visit: www.evgen.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RESBMBFTMTIBBIM
(END) Dow Jones Newswires
November 11, 2020 02:00 ET (07:00 GMT)
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From Apr 2023 to Apr 2024